NAIVE PATIENTS TREATED WITH SECOND-GENERATION ANTI-PYSCHOTIC

Screening visit

Inclusion visit N=15

• Introduction of SGA
• Informed consent
• Somatic parameters
• ECG
• Scales: K-SADS, BPRS, PANSS, SANS, YMRS, MADRS, ESRS, BFCRS
• Laboratory tests

At 2 weeks N=12

• Somatic parameters
• Scales: ESRS, BFCRS

STOP MONITORING (N=3)
2 catatonia
1 acute dystonia

At 6 weeks N=12

• Somatic parameters
• Scales: ESRS, BFCRS

At 12 weeks N=12

• Somatic parameters
• ECG
• Scales: ESRS, BFCRS
• Laboratory tests

ADVERSE EVENTS

TOTAL GROUP (N=15)
Muscle weakness (8/15), extrapyramidal syndrome (8/15), akathisia (6/15), acute oro-facial dystonia (3/15), catatonia (2/15)

COMPLETED GROUP (N=12)
Weight gain of ~8 kg
BMI increased significantly (p = 0.002)